TP53 and non-small cell lung carcinoma: Transgenic mouse models of oncogene-, for example Kras- or Egfr-driven NSCLC, demonstrate this principle nicely through a paucity of concomitant genetic alterations [64], but a dramatic phenotypic change upon TP53 loss with metastases and earlier death [65].